Nephros Inc.
NEPH Healthcare Medical Instruments & Supplies
Nephros Inc.’s revenue for fiscal 2025 (year ended December 2025) was $18.8 million, up 32.7% from fiscal 2024. In the quarter to June 2026, revenue grew 36.2%, EPS grew 450.0% and free cash flow fell 31.5%, each against the same quarter a year earlier.
Follow NEPH
Nephros Inc. (NEPH) P/E ratio
As of 16 October 2026, Nephros Inc. (NEPH) trades at a P/E ratio of 23.4×. Over the past ten years it has ranged from 0.0× (March 2025) to 71.4× (June 2025); the current reading is higher than 88% of that period. That is below the Medical Instruments & Supplies industry median of 33.8× and in line with the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 46.1× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 22.9× | (49.40%) |
| Mar 2026 | 45.3× | (1.81%) |
| Dec 2025 | 46.1× | 26.77% |
| Sep 2025 | 36.4× | 6.75% |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RVP Retractable Technologies, Inc. compare | n/m |
| MBOT Microbot Medical Inc. compare | n/m |
| POCI Precision Optics Corp. compare | n/m |
| MLSS Milestone Scientific, Inc. compare | n/m |
| HBIO Harvard Bioscience, Inc. compare | n/m |
| BNGO Bionano Genomics, Inc. compare | n/m |
| ZTEKF Zentek Ltd. compare | n/m |
| DXR Daxor Corporation compare | 4.7× |
| NEPH Nephros Inc. | 23.4× |
| Medical Instruments & Supplies industry median | 33.8× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)